Celcuity Inc. (CELC)
After hours:
| Previous Close | 11.48 |
| Open | 11.24 |
| Bid | 10.99 x 3000 |
| Ask | 11.07 x 1000 |
| Day's Range | 10.53 - 11.64 |
| 52 Week Range | 10.44 - 33.01 |
| Volume | |
| Avg. Volume | 33,488 |
| Market Cap | 164.108M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings Date | Feb. 14, 2022 - Feb. 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.75 |
- ACCESSWIRE
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
* FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients * On track to finalize Phase 3 clinical trial design for gedatolisib with FDA feedback in first quarter * Planning to initiate two studies in breast cancer to evaluate gedatolisib in patients selected with a CELsignia testMINNEAPOLIS, MN / ACCESSWIRE / January 18, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology comp
- ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D)MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today presented a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS) with updated results from a four-arm Phase 1b expansion stu
- ACCESSWIRE
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that an abstract has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in-person from December 7-10, 2021.
